The goal in cancer immunotherapy is to use a therapeutic antibody, molecule, or vaccine as a drug to activate the patient’s immunity. Upon stimulation, the patient’s immune system should recognize the tumor as foreign and an anti-tumor immune response should follow.
In clinical trials it is important to measure the patient’s anti-tumor immune response. Measuring the patient’s immune status before and during the trial provides greater understanding of the drug’s effectiveness. A correlative relationship between patient immunity and clinical outcome offers an opportunity to identify those patients most likely to benefit from treatment.
One major success story in cancer immunotherapy is the development of Yervoy® (ipilimumab) from Bristol-Myers Squibb for treating melanoma. Yervoy® is a recombinant, human monoclonal antibody that blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4), subsequently enabling T-cell mediated anti-tumor immune response. During clinical trials for Yervoy® there was considerable progress in the methods used to monitor anti-tumor immunity. At the very forefront of this effort were the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan Kettering Cancer Center (MSKCC), whose methods for immune monitoring represent the standard in immune monitoring.
The immune monitoring assays developed by the LICR and others enable effective measurement of anti-cancer immunity in immunotherapy patients and pave the way for predicting patient responses. Serametrix has partnered with the world’s leading tumor immunologists to make these immune monitoring tools openly available to pharmaceutical companies developing cancer immunotherapies. We help design the study, run the assays, and analyze and interpret the results.
To discuss ideas for your study or request a quote, click here.